This is a routine internal role consolidation with no financial or operational implications. The recent DEFA14A proxy solicitation (April 29) suggests board-level activity, but this filing is unrelated. No trading action warranted.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 18 $3.22entry
- T+1 · 6mo ago −3.42%α −2.77% · $3.11
- T+5 · 6mo ago +8.39%α +6.77% · $3.49
- T+20 · 5mo ago +19.25%α +17.67% · $3.84
- T+60 · 3mo ago +21.12%α +16.27% · $3.90
Price Chart
How similar events traded
Executive Summary
C4 Therapeutics disclosed the departure of Chief Accounting Officer Mark Mossler, effective May 15, 2026, with no disagreement cited. CFO Kendra R. Adams has been appointed as the new principal accounting officer without additional compensation. This is a routine internal role consolidation, not a red-flag departure.
Key Facts
- Mark Mossler will cease serving as Chief Accounting Officer effective May 15, 2026.
- Departure is explicitly stated as not due to any disagreement with the company or board on financial reporting, operations, policies, or practices.
- CFO Kendra R. Adams has been designated as the new principal accounting officer, effective May 15, 2026.
- Adams will receive no additional compensation for assuming the principal accounting officer role.
- A DEFA14A proxy filing from April 29, 2026 (16 days prior) indicates recent contested election or solicitation activity.
Financial Impact
No financial impact. Role consolidation with no compensation change.
Risk Factors
- No material risks identified from this filing alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-035542 |
| Document: 0001628280-26-035542-index-headers.html | 0001628280-26-035542 |
| Document: 0001628280-26-035542-index.html | 0001628280-26-035542 |
| Document: 0001628280-26-035542.txt | 0001628280-26-035542 |
Track record
19 reports on CCCC
5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers